Results 31 to 40 of about 8,055 (251)

Tirzepatide - a novel dual GLP-1 and GIP receptor agonist used in pharmacotherapy of obesity: A literature review

Journal of Education, Health and Sport, 2023
Background: Obesity is a chronic disease, which along with its complications, poses a huge threat to both our health as individuals and our healthcare as a community.
Bartłomiej Stachyra, Marta Wolanin, Cezary Stawikowski, Bartłomiej Zielonka, Aleksandra Osińska, Izabela Wolanin, Karolina Madej, Barbara Dengler, Ilona Kowalczyk, Paulina Krawiec   +9 more
doaj   +1 more source

Metabolic Memory in Cardiovascular Disease: Encoding, Propagation, and Therapeutic Targeting

Advanced Science, EarlyView.
Cardiovascular risk often persists after metabolic abnormalities are corrected. This conceptual Review frames such persistence as metabolic memory, encoded through a narrowing therapeutic window from reversible marks to irreversible damage, with continuous input from peripheral organs.
Cheng Cheng, Minghui Tang, Zhaobo Zhang, Ruoyi Qu, Jianfei Pei, Tian Liu, Siyao Qu, Shilong You, Shenshen Cui, Wenke Wang, Rui Zhao, Yingxian Sun, Naijin Zhang   +12 more
wiley   +1 more source

OAF Blocks SIAH1‐Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD

Advanced Science, EarlyView.
This study shows OAF directly binds to SCPX and inhibits its interaction with the E3 ligase SIAH1, thereby protecting SCPX from ubiquitin‐dependent degradation and stabilizing its levels. This OAF‐SCPX axis represents a novel pathway in lipid homeostasis, highlighting OAF as a promising therapeutic candidate for MASLD.
Zongxi Li, Jingyue Song, Kaili Ma, Shunan Tang, Shuqian Wang, Wenya Ji, Chen Lu, Ting Zhang, Huaping Zheng, Xiaowei Zheng, Shanshan Lai, Cheng Deng   +11 more
wiley   +1 more source

Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis

Cardiovascular Diabetology
Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used therapies for cardiovascular risk reduction in type 2 diabetes (T2D).
Arveen Shokravi, Jayant Seth, G.B. John Mancini   +2 more
doaj   +1 more source

Expert Consensus on the Management of Obesity in Older Adults (2026 Edition)

AGING MEDICINE, EarlyView.
This graphical abstract summarizes a safety‐first framework for managing obesity in older adults, with attention to age, functional status, comorbidities, and sarcopenia risk. Key assessments include BMI, waist measures, body fat percentage, skeletal muscle mass, and comprehensive geriatric evaluation. Management prioritizes reducing visceral fat while
Qi Pan, Lixin Guo
wiley   +1 more source

The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist

Journal of Lipid and Atherosclerosis, 2023
Glucagon-like peptide-1 (GLP-1) receptor agonists have been used extensively in the clinic and have an established safety profile in cardiovascular disease settings.
Yun Kyung Cho, Yoo La Lee, Chang Hee Jung   +2 more
doaj   +1 more source

Tirzepatide-induced ketoacidosis in non-diabetic patients [PDF]

Background: Tirzepatide is a novel glucagon-like peptide 1/glucose-dependent insulinotropic peptide (GLP-1/GIP) receptor agonist. It was recently approved for diabetes control and weight reduction in non-diabetic patients. Case description: We report the
Pathan Mohamad Rafe Iqbal, Ossama Sajeh Maadarani, Zouheir Ibrahim Bitar   +2 more
core   +1 more source

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial

Arthritis &Rheumatology, EarlyView.
Objective Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult participants with active PsA and overweight with at least one weight‐related comorbidity or obesity.
Joseph F. Merola, Philip Mease, Alan Kivitz, Naveed Sattar, Laura C. Coates, Daniel Aletaha, Cynthia E. Kartman, Peter Fischer, Luna Sun, Píndaro Martínez‐Osuna, Andris Kronbergs, Purvi Prajapati, Anabela Cardoso, Mark C. Genovese, Alexis Ogdie   +14 more
wiley   +1 more source

Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics

Lipids in Health and Disease
Clinical studies have suggested that tirzepatide may also possess hepatoprotective effects; however, the molecular mechanisms underlying this association remain unclear.
Jinliang Liang, Huanyi Liu, Guo Lv, Xiaotong Chen, Zhaoshou Yang, Kunhua Hu, Hongyan Sun   +6 more
doaj   +1 more source

Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus [PDF]

Endocrinology and Metabolism
Tirzepatide has demonstrated greater efficacy than semaglutide in improving glycemic control and reducing body weight in patients with type 2 diabetes mellitus (T2DM).
Noboru Kurinami, Masafumi Takada, Seigo Sugiyama, Akira Yoshida, Kunio Hieshima, Tomoko Suzuki, Fumio Miyamoto, Keizo Kajiwara, Katsunori Jinnouchi, Kenji Ashida, Masatoshi Nomura, Hideaki Jinnouchi   +11 more
doaj   +1 more source